Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized Trial Comparing Atezolizumab Versus Atezolizumab Plus Bevacizumab as First-line Treatment in PD-L1+ Advanced Metastatic Non-small-cell Lung Cancer Patients

NCT03896074 is registered in ClinicalTrials.gov with Fondazione Ricerca Traslazionale as lead sponsor.

NCT NCT03896074
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03896074 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized Trial Comparing Atezolizumab Versus Atezolizumab Plus Bevacizumab as First-line Treatment in PD-L1+ Advanced Metastatic Non-small-cell Lung Cancer Patients
Lead sponsor
Fondazione Ricerca Traslazionale
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 2, 2020
Completion date
May 31, 2027
Enrollment
206 (estimated)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

non-small-cell lung cancer patients